A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Study summary

A study to assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer in terms of efficacy, safety and tolerability

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedMEDI4736

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · Locally advanced · Metastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Apr 6, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 2

Interventional

Where is it offered?139 U.S. locations

Locations may change over time.

Who runs it?AstraZeneca

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 2
Sponsor: AstraZeneca
Interventions being studied: Drug: MEDI4736

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Non-small cell lung cancer (NSCLC)→

Disease setting

Locally advanced→Metastatic or stage IV→

Treatment approach

Immunotherapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Aged at least 18 years.
Documented evidence of NSCLC (stage IIIB/IV disease)
Disease progression or recurrence after both a platinum-based chemotherapy and at least 1 additional regimen for treatment of NSCLC
World Health Organisation (WHO) Performance Status of 0 or 1
Estimated life expectancy of more than 12 weeks
Patient's tumour sample must be PD-L1 positive (≥25%of tumour cells with membrane staining (Cohort 1 and 2) or PD-L1 positive with ≥90% of tumour cells with membrane staining (Cohort 3))

Reasons someone may not be able to joinExclusion criteria

Prior exposure to any anti-PD-1 or anti-PD-L1 antibody
Brain metastases or spinal cord compression or unless asymptomatic, treated and stable (not requiring steroids).
Active or prior autoimmune disease or history of immunodeficiency
Evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses or active infections including hepatitis B, C and HIV.
Evidence of uncontrolled illness such as symptomatic congestive heart failure, uncontrolled hypertension or unstable angina pectoris.
Any unresolved toxicity CTCAE \>Grade 2 from previous anti-cancer therapy.
Any prior Grade ≥3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE \>Grade 1
Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis)

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Research SiteGoodyear, Arizona
Research SiteSanta Rosa, California
Research SiteNew Haven, Connecticut
Research SitePort Saint Lucie, Florida
Research SiteTampa, Florida
Research SiteLawrenceville, Georgia
Research SiteWaterloo, Iowa
Research SiteTopeka, Kansas
Research SiteBethesda, Maryland
Research SiteBurlington, Massachusetts
Research SiteWorcester, Massachusetts
Research SiteSaint Louis Park, Minnesota

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 6, 2026. Always confirm current availability with the study team.

View original record ↗